HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified)

HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified)

• Background: Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.
• Description: HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H7) is expressed from human 293 cells (HEK293).
• Specifications: This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 56.1 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Expression Region: Gln 26- Leu 513
• Host: HEK 293
• Target: Prefusion glycoprotein F0/pre-F protein (RSV)
• Conjugation: Unconjugated
• Tag: C-10×His
• Source: Human respiratory syncytial virus A (strain A2)
• Stability: The product MUST be stored at -70°C or lower upon receipt; -70°C for 3 months under sterile conditions.
• Endotoxin: 1.0 EU per μg
• Purity: 95%
• Bioactivity: Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.2-1 ng/mL (QC tested).
• Format: Liquid
• Buffer: 0.1 M Sodium citrate, 150 mM NaCl, pH5.5
• Additives: Trehalose
• Molecular Weight: 56.1 kDa
• Shipping Conditions: Dry ice
• Storage Conditions: -70°C